Monocyte Deactivation in Neutropenic ARDS Patients Treated with G-CSF
Author Information
Author(s): Mokart Djamel, Kipnis Eric, Guerre-Berthelot Pierre, Vey Norbert, Capo Christian, Sannini Antoine, Brun Jean-Paul, Blache Jean-Louis, Mege Jean-Louis, Blaise Didier, Guery Benoit P
Primary Institution: Paoli-Calmette Institute
Hypothesis
Monocytes could play a major role, in addition to neutropenia, in the immunosuppression of neutropenic patients treated with granulocyte colony-stimulating factor (G-CSF) and presenting septic ARDS.
Conclusion
The study observed a systemic deactivation of monocytes in septic neutropenic ARDS patients, contributing to overall immunodeficiency.
Supporting Evidence
- Neutropenic patients showed lower baseline cytokine levels compared to non-neutropenic patients.
- Monocytes from neutropenic patients did not increase cytokine production in response to LPS stimulation.
- The mortality rate was significantly higher in neutropenic patients than in non-neutropenic patients.
Takeaway
In patients with a low white blood cell count, their immune cells called monocytes don't work well, which can make them sicker.
Methodology
Twenty-two patients with cancer were enrolled in a prospective observational study, divided into neutropenic and non-neutropenic groups, and their monocyte cytokine production was evaluated in vitro.
Potential Biases
The study did not evaluate monocyte HLA-DR expression due to profound leukopenia in neutropenic patients.
Limitations
The control population had solid organ malignancies, and the study did not analyze other parameters reflecting monocyte functions.
Participant Demographics
Patients were cancer patients with septic ARDS, divided into neutropenic (n=12) and non-neutropenic (n=10) groups.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website